Why the study?
Does tailored use of tirofiban reduce periprocedural myocardial damage in patients with NSTE-ACS and high residual platelet activity undergoing PCI?
Does tailored use of tirofiban reduce periprocedural myocardial damage in patients with NSTE-ACS and high residual platelet activity undergoing PCI?
Tailored administration of tirofiban does not reduce periprocedural myocardial damage or myonecrosis in NSTE-ACS patients with high residual platelet activity undergoing PCI.
Answers are grounded in this paper and cite their sources.
Does not reduce periprocedural myocardial damage with tailored tirofiban in NSTE-ACS with HPR; challenges hypothesis of benefit.
BACKGROUND: We conducted a randomized controlled trial to investigate whether an additional platelet inhibition with tirofiban would reduce the extent of myocardial damage and prevent periprocedural myonecrosis in patients with Non-ST-elevation acute coronary syndrome (NSTE-ACS) with a high residual platelet activity (HPR). METHODS: reaction unit (PRU) > 230, were randomly assigned to group A (tirofiban treatment, n = 30) or C1 (n = 30) and patients without an HPR to C2 (n = 78). Periprocedural myocardial damage was assessed using the area under the curve (AUC) of serial cardiac enzyme levels from the time of the procedure to post-36 h. Periprocedural myonecrosis incidence was evaluated. RESULTS: The troponin I AUC was not different between the groups (197.2 [41.5395.7], 37.9 [8.9313.9], 121.3 [43.7481.8] h∙ng/mL; p = 0.088). The results did not change when the baseline levels were adjusted (365.3 [279.5, 451.1], 293.0 [207.1, 379.0], and 298.0 [244.7, 351.3] h∙ng/mL; p = 0.487). The rate of periprocedural myonecrosis was also not different between the groups (53.0% vs. 50.0% vs. 33.3%, p = 0.092). The CK-MB isoenzyme analysis showed similar results. No difference in complications was noted. CONCLUSION: Additional tirofiban administration was not beneficial to patients with NSTE-ACS even with an HPR. TRIAL REGISTRATION: Clinical trial no. NCT03114995 , registered 11 April, 2017, retrospectively.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: